BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wang JS, Liu JC. Intestinal microbiota in the treatment of metabolically associated fatty liver disease. World J Clin Cases 2022; 10(31): 11240-11251 [PMID: 36387806 DOI: 10.12998/wjcc.v10.i31.11240]
URL: https://www.wjgnet.com/1007-9327/full/v10/i31/11240.htm
Number Citing Articles
1
Bianca M. Leca, Lukasz Lagojda, Chris Kite, Emmanouil Karteris, Eva Kassi, Harpal S. Randeva, Ioannis Kyrou. Maternal obesity and metabolic (dysfunction) associated fatty liver disease in pregnancy: a comprehensive narrative reviewExpert Review of Endocrinology & Metabolism 2024; 19(4): 335 doi: 10.1080/17446651.2024.2365791
2
Ludovico Abenavoli, Giuseppe Guido Maria Scarlata, Emidio Scarpellini, Luigi Boccuto, Rocco Spagnuolo, Bruno Tilocca, Paola Roncada, Francesco Luzza. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic SyndromeMedicina 2023; 59(3): 594 doi: 10.3390/medicina59030594
3
Chaiyavat Chaiyasut, Bhagavathi Sundaram Sivamaruthi, Narissara Lailerd, Sasithorn Sirilun, Subramanian Thangaleela, Suchanat Khongtan, Muruganantham Bharathi, Periyanaina Kesika, Manee Saelee, Thiwanya Choeisoongnern, Pranom Fukngoen, Sartjin Peerajan, Phakkharawat Sittiprapaporn. Influence of Bifidobacterium breve on the Glycaemic Control, Lipid Profile and Microbiome of Type 2 Diabetic Subjects: A Preliminary Randomized Clinical TrialPharmaceuticals 2023; 16(5): 695 doi: 10.3390/ph16050695